---
author: Harvey Guo
created: 2024-08-23 09:10
modified: 2024-08-23 09:10
aliases:
  - ADHD
share: true
---
# Epidemiology
---


# Etiology
---


# Pathophysiology
---


# Clinical features
---


# Diagnostics
---


# Treatment
---
Options include stimulant and nonstimulant therapy.
<span style="background:rgba(240, 200, 0, 0.2)">Stimulant therapy is usually first-line treatment</span> for children ≥ 6 years of age and adults. 
## Stimulant therapy
- Options: <span style="background:rgba(240, 200, 0, 0.2)">methylphenidate or amphetamine analogues (e.g., lisdexamfetamine, dextroamphetamine)</span>
- Mechanism of action: indirect and central sympathomimetic activity → increased release and blocked reuptake of norepinephrine and dopamine (minor effect on serotonin) → <span style="background:rgba(240, 200, 0, 0.2)">increased concentration of norepinephrine and dopamine in the synaptic cleft → increased mental performance (e.g., improved concentration, cognition, short-term memory) and fine motor skills</span>
- Adverse effects 
	- Sympathomimetic effects
		- Anxiety, agitation, restlessness, bruxism, tics 
		- Difficulty falling asleep ([[Insomnia disorder|insomnia]])
		- <span style="background:rgba(240, 200, 0, 0.2)">Reduced appetite</span>, nausea, vomiting, weight loss
		- Increased arterial <span style="background:rgba(240, 200, 0, 0.2)">blood pressure, tachycardia</span>
## Nonstimulant therapy
- [[Antidepressants|SSRI]]
	- Options: <span style="background:rgba(240, 200, 0, 0.2)">atomoxetine</span> or viloxazine
- Alpha-2 adrenergic agonists
	- Options: <span style="background:rgba(240, 200, 0, 0.2)">guanfacine</span> extended-release or <span style="background:rgba(240, 200, 0, 0.2)">clonidine</span> extended-release